Quotables
"We live in a society exquisitely dependent on science and technology, in which hardly anyone knows anything about science and technology."
Carl Sagan
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178494 | Modified human growth hormone formulations with an increased serum half-life Formulations of modified growth hormone polypeptides are provided, including human growth hormone polypeptides with one or more non-naturally encoded amino acids with an increased half-life. ... | 05/15/2012 |
| 8173782 | Fusion protein comprising growth hormone and growth hormone receptor Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents. ... | 05/08/2012 |
| 8168590 | Use of proteolysis resistant active VEGF The invention relates to vascular endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF a... | 05/01/2012 |
| 8153771 | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency Mutants of human FGF-1 are disclosed having increased stability and mitogenic potency. In the FGF-1 polypeptide, primarily residue 12 is substituted with threonine and/or residue 134 is substituted cysteine, valine or threonine to render the polypeptide more stable ... | 04/10/2012 |
| 8153770 | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency Mutants of human FGF-1 are disclosed having increased stability and mitogenic potency. In the FGF-1 polypeptide, primarily residue 12 is substituted with cysteine and/or residue 134 is substituted cysteine, valine or threonine to render the polypeptide more stable a... | 04/10/2012 |
| 8153585 | Peptide antagonists of vascular endothelial growth factor and methods of use thereof The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment of subjects having a disease or disorder associated with VEGF activity or subjects having tumors expressing a VEGF receptor. Th... | 04/10/2012 |
| 8148500 | Method of preparing cysteine mutants of human recombinant GM-CSF The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues t... | 04/03/2012 |
| 8129341 | Methods for treating diabetic wounds The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment. ... | 03/06/2012 |
| 8119776 | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency Mutants of human FGF-1 are disclosed having increased stability and mitogenic potency. In the FGF-1 polypeptide, primarily residue 12 is substituted with valine and residue 134 is substituted cysteine or threonine to render the polypeptide more stable and/or to incr... | 02/21/2012 |
| 8114836 | Long-acting veterinary polypeptides and methods of producing and administering same A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of t... | 02/14/2012 |
| 8106171 | Nel-related type 1 polypeptide The present invention provides novel human genes, for example a novel human gene comprising a nucleotide sequence coding for the amino acid sequence shown under SEQ ID NO:1. The use of the genes makes it possible to detect the expression of the same in various tissu... | 01/31/2012 |
| 8088899 | Human granulocyte-colony stimulating factor isoforms Disclosed is a novel physiologically active protein, which is a human granulocyte colony stimulating factor isoform, constructed in order to increase the in vivo lifetime of human granulocyte colony sedtimulating factor. The human granulocyte colony stimulating fact... | 01/03/2012 |
| 8067365 | Erythropoietin for treatment of multi-organ failure The compositions and methods disclosed herein are for prevention or treatment of multi-organ failure with erythropoietin. The usefulness of the present invention is that erythropoietin may act to prevent the onset of MOF in a patient at risk of developing it. The pr... | 11/29/2011 |
| 8067368 | Vascular endothelial growth factors and methods of their use Vascular endothelial growth factor alternative splice variants and methods of their use are provided. ... | 11/29/2011 |
| 8053408 | Methods for treating obesity using fibroblast growth factor-like polypeptides The present invention provides methods for reducing body weight in a mammal using Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. ... | 11/08/2011 |
| 8044182 | Adiponectin and uses thereof The invention provides methods and reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic ... | 10/25/2011 |
| 8030274 | Method for treating asthma and chronic obstructive pulmonary disease (COPD) comprising administering FGF2 The present invention relates an agent comprising FGF2 (Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor (bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease (COPD). Also, The present inventio... | 10/04/2011 |
| 8030275 | Methods for treating obesity using fibroblast growth factor-like polypeptides The present invention provides methods for reducing body weight in a mammal using Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. ... | 10/04/2011 |
| 8030273 | Protracted exendin-4 compounds Novel protracted exendin-4 compounds and therapeutic uses thereof. ... | 10/04/2011 |
| 8022191 | PEG-conjugated erythropoietin The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing phy... | 09/20/2011 |
| 8008456 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides Non-natural amino acids and polypeptides with non-natural amino acids are disclosed. Further, polypeptides with non-natural amino acids that are subject to post-translational modification are disclosed. Additionally, methods of making, purifying, and using non-natur... | 08/30/2011 |
| 7998930 | Modified growth hormones Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.... | 08/16/2011 |
| 7981864 | Methods and compositions for targeting proteins across the blood brain barrier Disclosed are methods and compositions for targeting therapeutic proteins to the brain. Methods and compositions of the invention involve associating an IGF moiety with a therapeutic protein in order to target the therapeutic protein to the brain. Soluble fusion pro... | 07/19/2011 |
| 7928061 | Methods of using VEGF-D polypeptides Disclosed herein are various uses for VEGF-D polypeptides. Exemplary uses include methods of stimulating endothelial cell proliferation, methods of stimulating vascular permeability, methods of stimulating angiogenesis and methods of activating VEGFR-2 and VEGFR-3 u... | 04/19/2011 |
| 7872107 | Interleukin-12p40 variants with improved stability Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have ... | 01/18/2011 |
| 7858582 | Ophthalmic hGM-CSF preparation The present invention provides an external preparation and the method for produce the same, in which said external preparation comprises recombinant human growth hormone or recombinant human granulocyte macrophage colony-stimulating factor and pharmaceutical accepta... | 12/28/2010 |
| 7855279 | Unstructured recombinant polymers and uses thereof The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these ... | 12/21/2010 |
| 7691981 | Growth factor homolog zvegf3 Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residu... | 04/06/2010 |
| 7671180 | Fibroblast growth factor-like polypeptides and variants thereof The present invention provides novel Fibroblast Growth Factor-like (FGF-like) fusion polypedtides. ... | 03/02/2010 |
| 7662932 | Vascular endothelial growth factor D (VEGF-D) polypeptides and methods of use The present invention provides VEGF-D polypeptides, which among other things stimulate endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as fragments, dimers, and methods of using the same. ... | 02/16/2010 |
| 7659379 | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency Mutants of human FGF-1 are disclosed having increased stability and mitogenic potency. In the FGF-1 polypeptide, primarily residues 12 and 134 are substituted with cysteine, valine or threonine to render the polypeptide more stable and/or to increase its mitogenicit... | 02/09/2010 |
| 7638607 | Urocortin proteins and uses thereof A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse CDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Bot... | 12/29/2009 |
| 7576190 | FGF-21 fusion proteins The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositi... | 08/18/2009 |
| 7557195 | Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF The present invention relates to a conjugate of a biocompatible polymer and a G-CSF bonded through a thiol group of a dysteine residue in G-CSF at a 1:1 molar ratio, and methods of preparation thereof. ... | 07/07/2009 |
| 7553941 | Long-acting polypeptides and methods of producing same A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a peptide-of-interest are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the inve... | 06/30/2009 |
| 7538197 | Use of neuregulin-β as an indicator and/or target The invention relates, inter alia, to the use of neuregulin-β as a target in a screening method for active compounds, in particular for exerting an influence on changes in calcium concentration which are mediated by glutamate receptors. The invention further... | 05/26/2009 |
| 7507799 | High affinity ligand for p75 neurotrophin receptor The present invention provides an isolated protein comprising a pro-domain of a proneurotrophin, methods for producing the protein, and pharmaceutical compositions containing the isolated protein. The invention also provides a nucleic acid molecule which encodes the... | 03/24/2009 |
| 7495087 | Cysteine muteins in the C-D loop of human interleukin-11 Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications. ... | 02/24/2009 |
| 7462700 | Canine RANKL and methods for preparing and using the same The present invention provides isolated nucleic acid molecules that encode a substantial part of canine RANKL polypeptide, including the extracellular domains of that polypeptide, the polypeptide and fragments thereof. Vectors and host cells encoding and expressing ... | 12/09/2008 |
| 7459541 | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing The present invention relates to compositions and methods for promoting tissue repair and regeneration. The invention provides a fusion polypeptide useful for targeting tissues for regeneration and methods of use therefore. ... | 12/02/2008 |
